drugset / Trial / NCT07050316
Intranasal Administration of Dodecyl Creatine Ester (CBT101) in Healthy Male Subjects
RandomizedParallel-groupQuadruple-blindOther
Summary
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled study to Evaluate the Safety, Tolerability,and Pharmacokinetics of Single and Multiple Ascending Doses of CBT101 given intranasally in Healthy Male Subjects.
Timeline
- Start
- 2025-03-14
- Primary completion
- 2025-09-26
- Completion
- 2025-09-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vebreltinib | Small molecule | 4.2 mg | Intranasal |
| Subject | Vebreltinib | Small molecule | 8.4 mg | Intranasal |